At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Botulinum Toxin Type A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
In Brief
A Phase 2 clinical trial evaluating Botulinum Toxin Type A and Placebo (saline) for Benign Prostatic Hyperplasia. Completed, enrolled 61 participants across 1 site.
Detailed Summary
This is a 24 week study evaluating the effects of botulinum toxin Type A on semen quality in patients with signs and symptoms of Benign Prostatic Hyperplasia (BPH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hyperplasia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartAug 2009
Primary CompletionJun 2012
Study CompletionAug 2012
TodayJul 2026
First PostedMay 7, 2009
Enrollment StartAug 1, 2009
Primary CompletionJun 1, 2012
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.2 years ago
Interventions
Botulinum Toxin Type Abiological
OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
Placebo (saline)drug
Saline injected into the prostate on Day 1.